🚀 VC round data is live in beta, check it out!
Mereo BioPharma Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mereo BioPharma Group and similar public comparables like Nicox, THX Pharma, Herantis Pharma, Xilio Therapeutics and more.
Mereo BioPharma Group Overview
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Founded
2015
HQ
Employees
36
Website
Sectors
Financials (LTM)
EV
$10M
Mereo BioPharma Group Financials
Mereo BioPharma Group reported last 12-month revenue of $7M and negative EBITDA of ($24M).
In the same LTM period, Mereo BioPharma Group generated $7M in gross profit, ($24M) in EBITDA losses, and had net loss of ($35M).
Revenue (LTM)
Mereo BioPharma Group P&L
In the most recent fiscal year, Mereo BioPharma Group reported revenue of $500K and EBITDA of ($40M).
Mereo BioPharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $500K | XXX | XXX | XXX |
| Gross Profit | $7M | XXX | $367K | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | ($24M) | XXX | ($40M) | XXX | XXX | XXX |
| EBITDA Margin | (366%) | XXX | (8021%) | XXX | XXX | XXX |
| EBIT Margin | (511%) | XXX | (7651%) | XXX | XXX | XXX |
| Net Profit | ($35M) | XXX | ($42M) | XXX | XXX | XXX |
| Net Margin | (527%) | XXX | (8376%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mereo BioPharma Group Stock Performance
Mereo BioPharma Group has current market cap of $51M, and enterprise value of $10M.
Market Cap Evolution
Mereo BioPharma Group's stock price is $0.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $51M | 0.3% | XXX | XXX | XXX | $-0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMereo BioPharma Group Valuation Multiples
Mereo BioPharma Group trades at 1.5x EV/Revenue multiple, and (0.4x) EV/EBITDA.
EV / Revenue (LTM)
Mereo BioPharma Group Financial Valuation Multiples
As of April 10, 2026, Mereo BioPharma Group has market cap of $51M and EV of $10M.
Equity research analysts estimate Mereo BioPharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mereo BioPharma Group has a P/E ratio of (1.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $51M | XXX | $51M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 20.6x | XXX | XXX | XXX |
| EV/EBITDA | (0.4x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | 28.0x | XXX | XXX | XXX |
| P/E | (1.5x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/FCF | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mereo BioPharma Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mereo BioPharma Group Margins & Growth Rates
Mereo BioPharma Group's revenue in the last 12 month grew by 262%.
Mereo BioPharma Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Mereo BioPharma Group's rule of 40 is 4580% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mereo BioPharma Group's rule of X is 11338% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Mereo BioPharma Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 262% | XXX | 4505% | XXX | XXX | XXX |
| EBITDA Margin | (366%) | XXX | (8021%) | XXX | XXX | XXX |
| EBITDA Growth | (172%) | XXX | (143%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 4580% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 11338% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 324% | XXX | 4602% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 261% | XXX | 3557% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 7725% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mereo BioPharma Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nicox | XXX | XXX | XXX | XXX | XXX | XXX |
| THX Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Herantis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Xilio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Moberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mereo BioPharma Group M&A Activity
Mereo BioPharma Group acquired XXX companies to date.
Last acquisition by Mereo BioPharma Group was on XXXXXXXX, XXXXX. Mereo BioPharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mereo BioPharma Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMereo BioPharma Group Investment Activity
Mereo BioPharma Group invested in XXX companies to date.
Mereo BioPharma Group made its latest investment on XXXXXXXX, XXXXX. Mereo BioPharma Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mereo BioPharma Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mereo BioPharma Group
| When was Mereo BioPharma Group founded? | Mereo BioPharma Group was founded in 2015. |
| Where is Mereo BioPharma Group headquartered? | Mereo BioPharma Group is headquartered in United Kingdom. |
| How many employees does Mereo BioPharma Group have? | As of today, Mereo BioPharma Group has over 36 employees. |
| Who is the CEO of Mereo BioPharma Group? | Mereo BioPharma Group's CEO is Denise Vera Scots-Knight. |
| Is Mereo BioPharma Group publicly listed? | Yes, Mereo BioPharma Group is a public company listed on Nasdaq. |
| What is the stock symbol of Mereo BioPharma Group? | Mereo BioPharma Group trades under MREO ticker. |
| When did Mereo BioPharma Group go public? | Mereo BioPharma Group went public in 2018. |
| Who are competitors of Mereo BioPharma Group? | Mereo BioPharma Group main competitors are Nicox, THX Pharma, Herantis Pharma, Xilio Therapeutics. |
| What is the current market cap of Mereo BioPharma Group? | Mereo BioPharma Group's current market cap is $51M. |
| What is the current revenue of Mereo BioPharma Group? | Mereo BioPharma Group's last 12 months revenue is $7M. |
| What is the current revenue growth of Mereo BioPharma Group? | Mereo BioPharma Group revenue growth (NTM/LTM) is 262%. |
| What is the current EV/Revenue multiple of Mereo BioPharma Group? | Current revenue multiple of Mereo BioPharma Group is 1.5x. |
| Is Mereo BioPharma Group profitable? | No, Mereo BioPharma Group is not profitable. |
| What is the current EBITDA of Mereo BioPharma Group? | Mereo BioPharma Group has negative EBITDA and is not profitable. |
| What is Mereo BioPharma Group's EBITDA margin? | Mereo BioPharma Group's last 12 months EBITDA margin is (366%). |
| What is the current EV/EBITDA multiple of Mereo BioPharma Group? | Current EBITDA multiple of Mereo BioPharma Group is (0.4x). |
| What is the current FCF of Mereo BioPharma Group? | Mereo BioPharma Group's last 12 months FCF is $25M. |
| What is Mereo BioPharma Group's FCF margin? | Mereo BioPharma Group's last 12 months FCF margin is 369%. |
| What is the current EV/FCF multiple of Mereo BioPharma Group? | Current FCF multiple of Mereo BioPharma Group is 0.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.